TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06680037: A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Sponsor: TG Therapeutics, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT06680037 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06680037 Rescue Dossier →